Capecitabine-Induced Hypertriglyceridemia and Hyperglycemia: Two Cases

Duman B. B., PAYDAŞ S., Tetiker T., Gunaldi M., Afsar C. U., Ercolak V., ...Daha Fazla

PHARMACOLOGY, cilt.90, ss.212-215, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 90
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1159/000342382
  • Dergi Adı: PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.212-215
  • Anahtar Kelimeler: Capecitabine, Hypertriglyceridemia, Breast cancer, Colorectal cancer, OF-THE-LITERATURE, CANCER, 5-FLUOROURACIL, CHEMOTHERAPY
  • Çukurova Üniversitesi Adresli: Evet

Özet

Capecitabine has shown significant antitumor activity against anthracycline/taxane refractory breast cancer and advanced colorectal carcinoma. The main drug-related adverse effects are palmar-plantar erythrodysesthesia (handfoot syndrome), diarrhea and stomatitis. Dyslipidemia is a rare but important side effect of this drug. The mechanism of capecitabine-induced hypertriglyceridemia (CI-HTG) is unclear. It may be due to the decreased activities of lipoprotein lipase and hepatic triglyceride lipase. This report is associated with 2 patients who developed severe HTG when receiving capecitabine. Capecitabine was discountinued and antilipemic treatments were given and both cases are in follow-up with normal lipid levels. This report describes CI-HTG and possible pathogenetic mechanisms and the literature is reviewed. Copyright (c) 2012 S. Karger AG, Basel